Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Approved Antiviral Drugs over the Past 50 Years
Erik De Clercq, Guangdi Li
Clinical Microbiology Reviews (2016) Vol. 29, Iss. 3, pp. 695-747
Open Access | Times Cited: 1284

Showing 1-25 of 1284 citing articles:

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Guangdi Li, Erik De Clercq
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 3, pp. 149-150
Open Access | Times Cited: 1791
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Maria L. Agostini, Erica L. Andres, Amy Sims, et al.
mBio (2018) Vol. 9, Iss. 2
Open Access | Times Cited: 1462
Host-directed therapies for bacterial and viral infections
Stefan H. E. Kaufmann, Anca Dorhoi, Richard S. Hotchkiss, et al.
Nature Reviews Drug Discovery (2017) Vol. 17, Iss. 1, pp. 35-56
Open Access | Times Cited: 617
The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold
Katherine L. Seley‐Radtke, Mary K. Yates
Antiviral Research (2018) Vol. 154, pp. 66-86
Open Access | Times Cited: 461
COVID-19: Drug Targets and Potential Treatments
Carmen Gil, Tiziana Ginex, Inés Maestro, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12359-12386
Open Access | Times Cited: 441
Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 420
Chemistry, structure and function of approved oligonucleotide therapeutics
Martin Egli, Muthiah Manoharan
Nucleic Acids Research (2023) Vol. 51, Iss. 6, pp. 2529-2573
Open Access | Times Cited: 410
In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Bhumi Shah, Palmi Modi, Sneha R. Sagar
Life Sciences (2020) Vol. 252, pp. 117652-117652
Open Access | Times Cited: 405
Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism
Valeria Cagno, Patrizia Andreozzi, Marco D’Alicarnasso, et al.
Nature Materials (2017) Vol. 17, Iss. 2, pp. 195-203
Open Access | Times Cited: 381
RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution
Sangita Venkataraman, Prasad Burra, R. Selvarajan
Viruses (2018) Vol. 10, Iss. 2, pp. 76-76
Open Access | Times Cited: 352
Programmable Inhibition and Detection of RNA Viruses Using Cas13
Catherine A. Freije, Cameron Myhrvold, Chloe K. Boehm, et al.
Molecular Cell (2019) Vol. 76, Iss. 5, pp. 826-837.e11
Open Access | Times Cited: 344
An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study
Sourav Das, Sharat Sarmah, Sona Lyndem, et al.
Journal of Biomolecular Structure and Dynamics (2020), pp. 1-11
Open Access | Times Cited: 338
Small-Molecule Antiviral β- d - N 4 -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
Maria L. Agostini, Andrea J. Pruijssers, James D. Chappell, et al.
Journal of Virology (2019) Vol. 93, Iss. 24
Open Access | Times Cited: 325
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
Xi Wang, Ruiyuan Cao, Huanyu Zhang, et al.
Cell Discovery (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 323
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Bo Han, Xiang‐Hong He, Yanqing Liu, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 3, pp. 1522-1586
Closed Access | Times Cited: 322
Epidemiology and Immune Pathogenesis of Viral Sepsis
Gu-Lung Lin, Joseph McGinley, Simon B. Drysdale, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 310
A review: Mechanism of action of antiviral drugs
Shamaila Kausar, Fahad Said Khan, Muhammad Ishaq Mujeeb Ur Rehman, et al.
International Journal of Immunopathology and Pharmacology (2021) Vol. 35
Open Access | Times Cited: 291
A materials-science perspective on tackling COVID-19
Zhongmin Tang, Na Kong, Xingcai Zhang, et al.
Nature Reviews Materials (2020) Vol. 5, Iss. 11, pp. 847-860
Open Access | Times Cited: 276
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Veaceslav Boldescu, Mira A. M. Behnam, Nikos Vasilakis, et al.
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 8, pp. 565-586
Open Access | Times Cited: 275
The ProTide Prodrug Technology: From the Concept to the Clinic
Youcef Mehellou, Hardeep S. Rattan, Jan Balzarini
Journal of Medicinal Chemistry (2017) Vol. 61, Iss. 6, pp. 2211-2226
Open Access | Times Cited: 272
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19
Minchen Chien, Thomas K. Anderson, Steffen Jockusch, et al.
Journal of Proteome Research (2020) Vol. 19, Iss. 11, pp. 4690-4697
Open Access | Times Cited: 272
Prodrugs in medicinal chemistry and enzyme prodrug therapies
Raoul Walther, Jarkko Rautio, Alexander N. Zelikin
Advanced Drug Delivery Reviews (2017) Vol. 118, pp. 65-77
Closed Access | Times Cited: 250
Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms
Bodee Nutho, Panupong Mahalapbutr, Kowit Hengphasatporn, et al.
Biochemistry (2020) Vol. 59, Iss. 18, pp. 1769-1779
Open Access | Times Cited: 248
Sanitizing agents for virus inactivation and disinfection
Qianyu Lin, Jason Y. C. Lim, Kun Xue, et al.
View (2020) Vol. 1, Iss. 2
Open Access | Times Cited: 243
Coumarin: An emerging antiviral agent
Shruti Mishra, Achyut Pandey, Siddharth Manvati
Heliyon (2020) Vol. 6, Iss. 1, pp. e03217-e03217
Open Access | Times Cited: 238
Page 1 - Next Page

Scroll to top